Loading
Neurogene Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Samsara BioCapital GP, LLC, was filed 27 Nov 2024.
Neurogene Inc.: what insiders have been doing
Neurogene Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 24 October 2025 to 24 October 2026, the disclosure feed for Neurogene Inc. logged 17 filings by 4 insiders.
There is no open-market purchase to report; the filings show 12 sales worth €577k by 4 insiders. Cvijic Christine Mikail filed the largest sale, €133k, on 7 July 2026, which represents 0.027% of the company's market value.
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 17 filings here. Since 2016, the database holds 128 purchases and 56 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -90.4 m USD.
Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
217
Thresholds
n/a
Buy Volume
€83M
128 ops. · all time
Sell Volume
€2M
56 ops. · all time
Who traded when
BuySaleChristine Mikail Cvijic1 buy8 sales
Samsara BioCapital GP, LLC4 buys
Stuart Cobb4 sales
Rachel McMinn1 buy1 sale
Julie Jordan1 sale
Since the insiders bought
- -17.1%Entry US$25.43 · Close at T+365 US$21.08
- -21.9%Entry US$26.87 · Close at T+365 US$20.99
- -21.9%Entry US$26.87 · Close at T+365 US$20.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Neurogene Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$77.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.40
Analyst consensus
8 analystsStrong buy
US$46.00Target US$77.88(+207%)US$166.00
Income statement
EBITDA-US$87.3M
Net income-US$90.4M0.0% margin
Valuation
PER (forward)-4.4x
P/Book1.9x
Beta2.09
Balance sheet & cash
Market capUS$508.3M
Total debtUS$11M
Free Cash Flow-US$78.4M
Debt / Equity4%
Profitability & ownership
ROE-45.3%
ROA-28.0%
% insiders7.0%
% institutions97.6%
Last declaration on 2 October 2026
Declarations217 total
756 shares@ US$25.320.0033% mcap1.7% of flowCommon StockSEC:0001606302-26-000007:0
600 shares@ US$36.0210.0038% mcap2.1% of flowCommon StockSEC:0001543663-26-000017:0
4,200 shares@ US$36.1340.027% mcap15.0% of flowCommon StockSEC:0001543663-26-000017:1
828 shares@ US$21.8932100.0% of flowCommon StockSEC:0001968554-26-000005:0
3,352 shares@ US$22.07496.5% of flowCommon StockSEC:0001606302-26-000005:0
2,558 shares@ US$21.62475.4% of flowCommon StockSEC:0001543663-26-000011:0
1,395 shares@ US$21.252.8% of flowCommon StockSEC:0001543663-26-000007:1
263 shares@ US$22.020.5% of flowCommon StockSEC:0001543663-26-000007:2
2,658 shares@ US$21.3422.9% of flowCommon StockSEC:0001994301-26-000004:1
148 shares@ US$22.081.3% of flowCommon StockSEC:0001994301-26-000004:2
2,387 shares@ US$20.42244.8% of flowCommon StockSEC:0001543663-26-000007:0
3,991 shares@ US$20.4143.4% of flowCommon StockSEC:0001994301-26-000004:0
4,800 shares@ US$25.109611.6% of flowCommon StockSEC:0001543663-26-000005:0
16,500 shares0Common StockSEC:0001994301-26-000002:0
4,900 shares0Common StockSEC:0001968554-26-000002:0
25,900 shares0Common StockSEC:0001606302-26-000002:0
22,000 shares0Common StockSEC:0001543663-26-000002:0
6,797 shares@ US$15.154256.6% of flowCommon StockSEC:0001404644-25-000046:0
23,900 shares0Common StockSEC:0001404644-25-000020:0
20,300 shares0Common StockSEC:0001404644-25-000023:0
8,400 shares0Common StockSEC:0001404644-25-000021:0
7,200 shares0Common StockSEC:0001404644-25-000025:0
4,501 shares@ US$16.947.9% of flowCommon StockSEC:0001404644-25-000007:0
20,748 shares@ US$24.91100.0% of flowCommon StockSEC:0001415889-24-027861:0
Canonical exit: 24 Feb 2025 (T+90)
10,803 shares@ US$26.0122.3% of flowCommon StockSEC:0001415889-24-027861:1
Canonical exit: 24 Feb 2025 (T+90)
25 of 217 declarations
About Neurogene Inc.
Neurogene Inc. (ticker: NGNE) is a U.S.-based biotechnology company listed on the Nasdaq market in the United States. It is focused on developing genetic medicines for rare neurological diseases, with a clinical-stage profile that makes the company highly dependent on trial execution, regulatory milestones and capital-market access. Neurogene was founded in January 2018 and is headquartered in New York, placing it in one of the most important U.S. hubs for biopharma research, financing and talent. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000037/ngne-20260331.htm?utm_source=openai))
The company’s lead asset is NGN-401, a gene therapy being developed for Rett syndrome, a severe neurodevelopmental disorder with limited treatment options. Neurogene has positioned NGN-401 as its primary value driver and has advanced it through clinical development, including a registrational study. The company has also emphasized its in-house manufacturing capabilities and broader development infrastructure, which it believes can support product quality, development timelines and the transition from clinical to commercial operations. Neurogene also references its EXACT platform and a broader pipeline, but the investment thesis is still largely centered on NGN-401. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-recent-achievements-and-anticipated-2026-key?utm_source=openai))
Read moreShow less
From a competitive standpoint, Neurogene operates in a niche but crowded gene-therapy landscape where differentiation is driven by clinical data, durability, safety, manufacturing reliability and eventual reimbursement potential. Its strategic focus on rare neurological diseases gives it a clear thematic identity, and management has repeatedly framed NGN-401 as potentially best-in-class for Rett syndrome. At the same time, the company remains exposed to the standard biotech risks: clinical setbacks, FDA scrutiny, manufacturing complexity and the need to secure sufficient funding before and after commercialization. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-recent-achievements-and-anticipated-2026-key?utm_source=openai))
Recent company updates have been constructive. In January 2026, Neurogene said multiple participants had been dosed in the Embolden registrational trial for NGN-401 and outlined 2026 milestones including additional clinical data, continued trial progress and commercial-readiness work. In March 2026, the company reported full-year 2025 financial results, and in May 2026 it reported first-quarter 2026 results. Recent SEC Form 4 filings also show ongoing insider transaction activity, which investors often monitor closely in development-stage biotech names. Overall, Neurogene remains a small-cap Nasdaq biotech story driven by a single lead program with meaningful upside if data continue to support the Rett syndrome thesis. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-recent-achievements-and-anticipated-2026-key?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
